Motivation allows us to energise actions when we expect reward and is reduced in
depression. This effect, termed motivational vigour, has been proposed to rely on central …

The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it
has also been thought to mediate impulsive behaviors in animal models. Most of the studies …

Rationale The dopaminergic system, particularly D2-like dopamine receptors, has been
strongly implicated in reward processing. Animal studies have emphasized the role of …

The efficacy of dopamine agonists in treating major depressive disorder has been
hypothesized to stem from effects on ventrostriatal dopamine and reward function. However …

Introduction Many depressed patients do not achieve remission with available treatments.
Anhedonia is a common residual symptom associated with treatment resistance as well as …

We can be motivated when reward depends on performance, or merely by the prospect of a
guaranteed reward. Performance-dependent (contingent) reward is instrumental, relying on …

Pramipexole is a clinically important dopamine receptor agonist with reported selectivity for
dopamine D3 receptors over other dopaminergic and non-dopaminergic sites. Many of its …

Dopaminergic mechanisms are a plausible treatment target for patients with clinical
depression but are relatively underexplored in conventional antidepressant medications …

Objective To investigate feasibility and target engagement of high‐dose, add‐on
pramipexole treatment in anhedonic depression. Method In this open‐label pilot study, we …

Abstract Rationale Pramipexole, a D 2/D 3 dopamine receptor agonist, has been implicated
in the development of impulse control disorders in patients with Parkinson's disease …